Results of Operations and Financial Condition. On August 10, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilit…

Results of Operations and Financial Condition. On May 15, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabiliti…

Other Events. The statistical powering assumption for the surrogate endpoint (eGFR slope) analysis in the PROACT 1 study has been updated to 80%, while the statistical powering assumption for the confirmatory endpoint analysis remains at 80%. Forward-Looking Statements The disclosure in this Current Report on Form 8-K and the attached exhibits include “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKid…

Results of Operations and Financial Condition. On March 18, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabili…

of this Current Report on Form 8-K. Forward-Looking Statements The disclosure in this Current Report on Form 8-K and the attached exhibit contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expe…

Results of Operations and Financial Condition. On November 10, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the…

Entry into a Material Definitive Agreement. As previously disclosed, on May 8, 2025, ProKidney Corp. (the “Company”), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC (“Acquisition Sub”), entered into a purchase and sale agreement with Williams Development Group, LLC (the “Williams Purchase Agreement”) to sell the Company’s property located in Greensboro, North Carolina. The Williams Purchase Agreement was subsequently terminated and, on October 17, 2025, the Company, t…

Results of Operations and Financial Condition. On August 12, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabili…

Entry into a Material Definitive Agreement. On July 14, 2025, ProKidney Corp. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its Class A common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $200,000,000 through the Sales Agent, acting as agent. Pursuant to the Sales Ag…

Termination of a Material Definitive Agreement. Effective July 14, 2025, the Open Market Sale Agreement SM dated January 19, 2024 by and between the Company and the Sales Agent (the “2024 Sales Agreement”) was mutually terminated. Under the 2024 Sales Agreement, the Company could sell from time to time, at its option, its Class A ordinary shares by any method that was deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. The 2024 Sales Agreement was t…

Other Events. The Company has filed a prospectus supplement (the “ATM Prospectus Supplement”) to the Registration Statement in connection with its Sales Agreement. Pursuant to the ATM Prospectus Supplement, the Company may, at its discretion from time to time, sell up to $200 million of Common Stock under its “at the market” program.

Results of Operations and Financial Condition. On May 12, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabiliti…

Results of Operations and Financial Condition. On March 17, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabili…

Entry into a Material Definitive Agreement. On January 17, 2025, ProKidney Corp. (the “Company”), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC, entered into a purchase and sales agreement with Stream Realty Acquisition, L.L.C. (the “Agreement”) to sell the Company’s real property located in Greensboro, North Carolina for approximately $20.5 million in cash. The Agreement contains customary representations for a transaction of this type. The transaction is expected t…

Entry into a Material Definitive Agreement. On November 20, 2024, ProKidney Corp. (the “Company”), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC, entered into a purchase agreement with Breit SE Industrial Propco NC LP (the “Agreement”) to purchase two buildings on adjacent parcels in Winston-Salem, North Carolina, portions of which buildings the Company now occupies pursuant to real estate leases. The two buildings represent total usable space of approximately 180,00…

Results of Operations and Financial Condition. On November 12, 2024, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the…

Other Events. On September 3, 2024, the Company issued a press release announcing strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced chronic kidney disease. A copy of the press release is filed as Exhibit 99.2 hereto and incorporated herein by reference. The disclosure in this report and the incorporated exhibits contains forward-looking statements within the meaning of th…

Results of Operations and Financial Condition. On August 9, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that s…

Entry into a Material Definitive Agreement. Underwriting Agreement On June 11, 2024, ProKidney Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the public offering of 42,744,220 shares of the Company’s Class A ordinary shares, $0.0001 par value per share (the “Ordinary Shares”),…

Other Events. On June 10, 2024, the Company announced REGEN-007 Phase 2 Trial Interim Efficacy & Safety Data as well as certain clinical and operational updates. On June 10, 2024, the Company also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the presentation. REGEN-007 Phase 2 Trial Interim E…

Results of Operations and Financial Condition. On May 10, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that se…

Executive Vice President, Technical Operations — Ulrich Ernst, Ph.D.: Dr. Ernst was hired as the Executive Vice President, Technical Operations.

Results of Operations and Financial Condition. On March 21, 2024, ProKidney Corp. issued a press release to announce its financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that…

null — Dr. Bertram: Dr. Bertram entered into a Separation Agreement with the company, indicating his departure.

Director or Certain Officer — Dr. Jain: Dr. Jain entered into a Separation Agreement with the company, indicating his departure.